恶唑烷酮类抗生素U-100592和U-100766对金黄色葡萄球菌和凝固酶阴性葡萄球菌的体外活性
In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species.
作者信息
Jorgensen J H, McElmeel M L, Trippy C W
机构信息
Department of Pathology, University of Texas Health Science Center, San Antonio 78284-7750, USA.
出版信息
Antimicrob Agents Chemother. 1997 Feb;41(2):465-7. doi: 10.1128/AAC.41.2.465.
Abstract
U-100592 and U-100766 are closely related antibiotics of the oxazolidinone class. Their in vitro activities were determined against 100 isolates of Staphylococcus aureus and 100 isolates of coagulase-negative Staphylococcus species by broth and agar dilution test methods. The MICs of both compounds by either test method at which 50 and 90% of isolates are inhibited were 2 and 4 micrograms/ml, respectively, for S. aureus and 1 to 2 micrograms/ml for coagulase-negative staphylococci. Time-kill assay with selected strains indicated a primarily bacteriostatic effect against staphylococci.
摘要
U - 100592和U - 100766是密切相关的恶唑烷酮类抗生素。通过肉汤稀释法和琼脂稀释法测定了它们对100株金黄色葡萄球菌和100株凝固酶阴性葡萄球菌的体外活性。两种化合物在两种测试方法中对50%和90%分离株产生抑制作用时的最低抑菌浓度（MIC），对金黄色葡萄球菌分别为2微克/毫升和4微克/毫升，对凝固酶阴性葡萄球菌为1至2微克/毫升。对选定菌株的时间 - 杀菌试验表明，其对葡萄球菌主要起抑菌作用。
相似文献
1
In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species.恶唑烷酮类抗生素U-100592和U-100766对金黄色葡萄球菌和凝固酶阴性葡萄球菌的体外活性
Antimicrob Agents Chemother. 1997 Feb;41(2):465-7. doi: 10.1128/AAC.41.2.465.
2
Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.恶唑烷酮类化合物依哌唑胺（PNU - 100592）和利奈唑胺（PNU - 100766）与万古霉素相比，对金黄色葡萄球菌、凝固酶阴性葡萄球菌、粪肠球菌和屎肠球菌的体外比较活性及抗生素后效应。
Antimicrob Agents Chemother. 1998 Mar;42(3):721-4. doi: 10.1128/AAC.42.3.721.
3
In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.新型恶唑烷酮类抗菌剂U-100592和U-100766的体外活性
Antimicrob Agents Chemother. 1996 Apr;40(4):839-45. doi: 10.1128/AAC.40.4.839.
4
In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.恶唑烷酮类化合物U100592和U100766对金黄色葡萄球菌和表皮葡萄球菌的体外活性
Antimicrob Agents Chemother. 1996 Mar;40(3):799-801. doi: 10.1128/AAC.40.3.799.
5
In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates.新型恶唑烷酮类药物AZD2563对603株近期葡萄球菌分离株的体外评估
Antimicrob Agents Chemother. 2002 Aug;46(8):2662-4. doi: 10.1128/AAC.46.8.2662-2664.2002.
6
In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.两种新型氟化恶唑烷酮U-100592和U-100766的体外抗菌活性及抗菌谱
Antimicrob Agents Chemother. 1996 Mar;40(3):720-6. doi: 10.1128/AAC.40.3.720.
7
In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci.替加环素（TR-700）对耐利奈唑烷葡萄球菌的体外活性。
J Antimicrob Chemother. 2012 Jan;67(1):167-9. doi: 10.1093/jac/dkr403. Epub 2011 Sep 27.
8
Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.莫西沙星、曲伐沙星、奎奴普丁/达福普汀及利奈唑胺对葡萄球菌的体外活性比较
J Antimicrob Chemother. 1999 Apr;43(4):569-73. doi: 10.1093/jac/43.4.569.
9
Linezolid resistance in coagulase-negative staphylococci.凝固酶阴性葡萄球菌对利奈唑胺的耐药性
J Antimicrob Chemother. 2006 Oct;58(4):898-9; author reply 899-900. doi: 10.1093/jac/dkl271. Epub 2006 Jul 19.
10
In vitro activities in new oxazolidinone antimicrobial agents against enterococci.新型恶唑烷酮类抗菌剂对肠球菌的体外活性
Antimicrob Agents Chemother. 1996 Jul;40(7):1745-7. doi: 10.1128/AAC.40.7.1745.
引用本文的文献
1
Linezolid compared with vancomycin for the prevention of methicillin-resistant Staphylococcus aureus or Staphylococcus epidermidis vascular graft infection in rats: A randomized, controlled, experimental study.利奈唑胺与万古霉素预防大鼠耐甲氧西林金黄色葡萄球菌或表皮葡萄球菌血管移植物感染的比较：一项随机对照实验研究。
Curr Ther Res Clin Exp. 2007 Jan;68(1):23-31. doi: 10.1016/j.curtheres.2007.02.001.
2
Newer antibacterial drugs for a new century.新世纪的新型抗菌药物。
Expert Opin Investig Drugs. 2010 Feb;19(2):215-34. doi: 10.1517/13543780903505092.
3
Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection.利奈唑胺单独或联合利福平治疗实验性异物感染中的耐甲氧西林金黄色葡萄球菌。
Antimicrob Agents Chemother. 2009 Mar;53(3):1142-8. doi: 10.1128/AAC.00775-08. Epub 2008 Dec 15.
4
A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins?恶唑烷酮类药物的批判性综述：糖肽类和链阳菌素类的替代物还是替代品？
Can J Infect Dis. 2001 Nov;12(6):379-90. doi: 10.1155/2001/260651.
5
Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci.六种抗微生物药物敏感性试验方法检测利奈唑胺对葡萄球菌和肠球菌的准确性
J Clin Microbiol. 2007 Sep;45(9):2917-22. doi: 10.1128/JCM.00913-07. Epub 2007 Jul 18.
6
In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.利奈唑胺联合其他抗菌药物对葡萄球菌、肠球菌、肺炎球菌及部分革兰阴性菌的体外活性。
Antimicrob Agents Chemother. 2003 Jun;47(6):1902-6. doi: 10.1128/AAC.47.6.1902-1906.2003.
7
In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus.利奈唑胺与万古霉素、庆大霉素、环丙沙星、夫西地酸和利福平联合应用对金黄色葡萄球菌的体外杀菌活性。
Antimicrob Agents Chemother. 2003 Jan;47(1):418-20. doi: 10.1128/AAC.47.1.418-420.2003.
8
Vancomycin resistance in staphylococci.葡萄球菌中的万古霉素耐药性。
Clin Microbiol Rev. 2002 Jul;15(3):430-8. doi: 10.1128/CMR.15.3.430-438.2002.
9
Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.利奈唑胺（PNU-100766）与苯唑西林-双氯西林治疗复杂性皮肤及软组织感染的随机对照研究
Antimicrob Agents Chemother. 2000 Dec;44(12):3408-13. doi: 10.1128/AAC.44.12.3408-3413.2000.
10
In vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin, and metronidazole against Helicobacter pylori.利奈唑胺单独及与阿莫西林、克拉霉素和甲硝唑联合应用对幽门螺杆菌的体外活性。
Antimicrob Agents Chemother. 2000 Jul;44(7):1977-9. doi: 10.1128/AAC.44.7.1977-1979.2000.
本文引用的文献
1
In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.恶唑烷酮类化合物U100592和U100766对金黄色葡萄球菌和表皮葡萄球菌的体外活性
Antimicrob Agents Chemother. 1996 Mar;40(3):799-801. doi: 10.1128/AAC.40.3.799.
2
In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.新型恶唑烷酮类抗菌剂U-100592和U-100766的体外活性
Antimicrob Agents Chemother. 1996 Apr;40(4):839-45. doi: 10.1128/AAC.40.4.839.
3
Multiple-antibiotic-resistant pathogenic bacteria. A report on the Rockefeller University Workshop.多重耐药病原菌。洛克菲勒大学研讨会报告。
N Engl J Med. 1994 Apr 28;330(17):1247-51. doi: 10.1056/NEJM199404283301725.
4
Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721.恶唑烷酮类，一类新型合成抗菌剂：DuP 105和DuP 721的体外及体内活性
Antimicrob Agents Chemother. 1987 Nov;31(11):1791-7. doi: 10.1128/AAC.31.11.1791.
5
Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds.新型恶唑烷酮化合物DuP 105和DuP 721的活性及作用机制
J Antimicrob Chemother. 1988 Jun;21(6):721-30. doi: 10.1093/jac/21.6.721.
6
In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents.新型恶唑烷酮类抗菌剂DuP 105和DuP 721的体外评价
Antimicrob Agents Chemother. 1988 Jan;32(1):150-2. doi: 10.1128/AAC.32.1.150.
7
Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis.DuP 721的作用机制：抑制蛋白质合成起始过程中的早期事件。
Antimicrob Agents Chemother. 1988 Aug;32(8):1218-22. doi: 10.1128/AAC.32.8.1218.
8
The crisis in antibiotic resistance.抗生素耐药性危机。
Science. 1992 Aug 21;257(5073):1064-73. doi: 10.1126/science.257.5073.1064.
9
Epidemiology of drug resistance: implications for a post-antimicrobial era.耐药性流行病学：对抗菌药物后时代的影响。
Science. 1992 Aug 21;257(5073):1050-5. doi: 10.1126/science.257.5073.1050.
Zotero 插件